Aandeel IMMP IMMUTEP ADR
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Immutep ADR Nasdaq

Aandelen

IMMP

US45257L1089

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 17-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
2,96 USD +1,37% Intraday-grafiek van Immutep ADR +2,78% +23,33%
18:01 IMMUTEP ADR : Capital One Securities verhoogt van Verkopen naar Kopen ZM
15/05 Immutep zegt dat veiligheidsinleidende fase van borstkankerstudie "bemoedigende" gegevens oplevert MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024
Immutep Quarterly Activities Report Q3 FY24
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers IMM
  4. Koers IMMP
  5. Nieuws Immutep ADR
  6. Andere talen